8-K: Kenvue Q3 2025: Sales Decline, Leadership Changes, Kimberly-Clark Merger

Kenvue reported a 3.5% net sales decrease in Q3 2025, affirmed its full-year outlook, and announced Kirk Perry as permanent CEO alongside a definitive merger agreement with Kimberly-Clark.

Summary

• Net sales decreased 3.5% to $3,764 million in the third quarter of 2025 compared to the prior year period.
• Organic sales declined 4.4%, primarily driven by a 4.0% volume decrease and 0.4% unfavorable value realization.
• Diluted earnings per share (EPS) increased to $0.21 from $0.20 in the prior year period.
• Adjusted diluted EPS remained flat at $0.28 year-over-year.
• Gross profit margin expanded 60 basis points to 59.1%, and Adjusted gross profit margin expanded 50 basis points to 61.2%.
• Operating income margin was 16.7% compared to 16.8% in the prior year, while Adjusted operating income margin was 21.5% compared to 22.1%.
• Kenvue affirmed its Full Year 2025 outlook, expecting Net sales and Organic sales to decline low-single-digits, Adjusted operating income margin to decline, and Adjusted diluted EPS to be in the range of $1.00 to $1.05.
• Kirk Perry was appointed permanent Chief Executive Officer, effective November 3, 2025.
• Carlos De Jesus was appointed Group President, North America, effective November 3, 2025.
• Jonathan Halvorson was appointed to the newly created role of Chief Digital and Marketing Officer, effective November 17, 2025.
• Kenvue announced it has entered into a definitive merger agreement under which Kimberly-Clark will acquire all outstanding shares of Kenvue common stock in a cash and stock transaction.
• The company will no longer host its previously planned quarterly conference call with investors due to the merger agreement.

Sentiment

Score: 6

Explanation: While financial performance shows declines in sales and operating margins, the affirmation of full-year guidance, strong gross margin expansion, and improved cash flow provide a degree of stability. The announced merger with Kimberly-Clark introduces significant strategic implications and potential for shareholder value realization, but also uncertainty until completion. Leadership changes are positive for strategic direction.

Positives

• Diluted EPS increased to $0.21 in Q3 2025 from $0.20 in the prior year period.
• Gross profit margin expanded 60 basis points to 59.1% in Q3 2025.
• Adjusted gross profit margin expanded 50 basis points to 61.2% in Q3 2025, reflecting savings from productivity gains attributable to global supply chain optimization initiatives.
• Effective tax rate reduced to 24.3% from 33.6% in the prior year, largely due to an increase in discrete tax benefits.
• Adjusted effective tax rate reduced to 24.0% from 28.9% in the prior year.
• Net cash flows from operating activities improved to $1.3 billion year-to-date through Q3 2025, up from $1.0 billion in the prior year period.
• Free cash flow improved to nearly $1.0 billion year-to-date through Q3 2025, up from $0.7 billion in the prior year period.
• Strong market share momentum for key brands, including Zyrtec (fastest growing, #1 for 17 consecutive quarters in Adult Allergy) and Tylenol (#1 Doctor and Pediatrician recommended, gained share for 13 consecutive quarters in U.S. Adult Pain).
• Neutrogena global consumption improved sequentially and turned positive for the first time since Q4 2023, with U.S. units growing year-over-year for the second consecutive quarter.
• Stabilized total distribution points across several major brands, including Neutrogena and OGX, after years of decline.
• Neutrogena gained share in Face on Amazon during October Prime Day for the first time in 2 years.
• BAND-AID brand was a major source of strength due to strong innovation launches.
• Aveeno Baby grew consumption and share both globally and in the U.S.
• Johnsons Baby continued to see strong share growth momentum in Brazil from innovation and strong in-store activation.
• Leadership team strengthened with the appointment of Kirk Perry as permanent CEO and two critical new hires, Carlos De Jesus and Jonathan Halvorson.

Negatives

• Net sales decreased 3.5% to $3,764 million in Q3 2025 compared to $3,899 million in the prior year period.
• Organic sales declined 4.4% in Q3 2025, driven by a 4.0% volume decrease and 0.4% unfavorable value realization.
• Operating income margin contracted to 16.7% from 16.8% in the prior year period.
• Adjusted operating income margin contracted to 21.5% from 22.1% in the prior year period.
• Volumes in Q3 2025 were impacted by changes in shipment timing in China, trade inventory reductions at certain customers, and sequential deceleration in the global weighted category growth rate due to low seasonal incidences impacting Self Care.
• Self Care Net sales decreased 3.8% year-over-year, with Organic sales declining 5.3%.
• Skin Health and Beauty Net sales decreased 3.2% year-over-year, with Organic sales declining 3.5%.
• Essential Health Net sales decreased 3.3% year-over-year, with Organic sales declining 4.2%.
• Value realization was unfavorably impacted by planned strategic price investments in the U.S.
• Oral Care performance continued to lag the category, particularly in North America.
• Adjusted operating income margin is expected to decline year-over-year for Full Year 2025.
• The Full Year 2025 Adjusted diluted EPS outlook includes a low-single-digit unfavorable impact from foreign currency.

Risks

• Inability to execute on Kenvue's business development strategy.
• Inflation and other economic factors, such as interest rate and currency exchange rate fluctuations, as well as existing or proposed tariffs and other constraints on trade.
• Inability to successfully manage local, regional, or global economic volatility, including reduced market growth rates.
• Inability to generate sufficient income and cash flow to allow Kenvue to effect any expected share repurchases and dividend payments.
• Kenvue's ability to maintain satisfactory credit ratings and access capital markets, which could adversely affect its liquidity, capital position, and borrowing costs.
• Competition, including technological advances, new products, and intellectual property attained by competitors.
• Challenges inherent in new product research and development and uncertainty of commercial success for new and existing products.
• Challenges to intellectual property protections including counterfeiting.
• Inability to successfully execute strategic plans, including 'Our Vue Forward' and other restructuring or cost-saving initiatives.
• The impact of business combinations and divestitures, including any ongoing or future transactions.
• Manufacturing difficulties or delays, internally or within the supply chain.
• Product efficacy or safety concerns resulting in product recalls or regulatory action.
• Significant adverse litigation or government action, including related to product liability claims (e.g., talc-based Johnson's Baby powder proceedings in the UK).
• Changes to applicable laws and regulations and other requirements imposed by stakeholders.
• Changes in behavior and spending patterns of consumers.
• Natural disasters, acts of war, or terrorism, catastrophes, or epidemics, pandemics, or other disease outbreaks.
• Financial instability of international economies and legal systems and sovereign risk.
• The inability to realize the benefits of the separation from Kenvue's former parent, Johnson & Johnson.
• The risk of disruption or unanticipated costs in connection with the separation.
• The Company's inability to consummate the proposed transaction with Kimberly-Clark due to market, regulatory, and other factors.
• The potential for disruption to the Company's business resulting from the proposed transaction with Kimberly-Clark.
• Potential adverse effects on the Company's stock price from the announcement, suspension, or consummation of the proposed transaction with Kimberly-Clark.

Future Outlook

Kenvue affirms its Full Year 2025 outlook, expecting Net sales and Organic sales to decline low-single-digits, assuming approximately neutral impact from foreign currency translation. Adjusted operating income margin is projected to decline year-over-year. Adjusted diluted earnings per share are expected to be in the range of $1.00 to $1.05, including a low-single-digit unfavorable impact from foreign currency. Stronger year-over-year performance in Net sales and Organic sales is anticipated for Q4 due to a robust innovation pipeline and easier base period comparisons.

Management Comments

• Kirk Perry: "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance. Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvues performance and unlock the inherent value of our brands."
• Kirk Perry: "I look forward to the continued partnership with the Board and Leadership team on executing on our strategic and financial goals."
• Kirk Perry: "I have worked with both Carlos and Jon in different capacities and have seen the transformative impact they both make in driving growth. With these two new hires, approximately half of our leadership team has been appointed in the last six months, and we are all highly focused on execution and performance."
• Amit Banati: "During the third quarter we continued to navigate through a dynamic external environment, as consumers remained cautious. While the Companys topline performance was impacted by similar dynamics that we experienced in the second quarter, and our global weighted category slowed sequentially, our team did an excellent job driving strong productivity and effectively managing costs."
• Amit Banati: "The combination of third quarter results and quarter-to-date performance in Q4 gives us confidence to reaffirm our outlook for 2025."
• Amit Banati: "Our #1 priority is to the consumers and healthcare professionals we serve every day. We remain committed to providing clarity to our consumers during this time of confusion, as well as continuing to deliver educational tools to pediatricians, doctors, and pharmacists to help them provide information on the safe use of acetaminophen for their patients."

Industry Context

The consumer health industry is navigating a dynamic external environment characterized by cautious consumers and a sequential slowdown in global weighted category growth rates. This slowdown is particularly evident in seasonal businesses within Self Care, impacted by low seasonal incidences for conditions like pediatric fever, cough, cold, and flu. Despite these headwinds, Kenvue's strong brand portfolio, including Tylenol and Zyrtec, continues to demonstrate market leadership and share gains, indicating resilience and effective innovation in competitive segments. The Skin Health and Beauty category is experiencing a significant shift towards eCommerce, necessitating accelerated digital transformation strategies to maintain market position and drive growth.

Comparison to Industry Standards

• Tylenol remains the #1 Doctor and #1 Pediatrician recommended brand of pain reliever, gaining share for 13 consecutive quarters in the U.S. Adult Pain category, strengthening its #1 market leadership.
• Zyrtec is the fastest-growing brand in the Allergy category, maintaining its #1 market position for 17 consecutive quarters on the Adult side.
• Nicorette's market share momentum is fueled by strong innovation, including approval of its product range for indication against vaping in the UK.
• Listerine is further solidifying its #1 Dentist & Hygienist Recommended position, with an increase in average weekly recommendations in the U.S.
• Kenvue is actively working to increase supplier payment terms closer to industry norms as part of its efforts to improve working capital.

Management Changes

Corporate Governance

Legal Proceedings

• Proceedings were issued in the UK related to the former talc-based Johnson's Baby powder offering.

Related Party Transactions

• Costs incurred in connection with the establishment of Kenvue as a standalone public company (Separation-related costs) are ongoing.
• The impact of the deferred transfer of certain assets and liabilities from Johnson & Johnson in certain jurisdictions (Deferred Markets) is noted.

Stakeholder Impact

• Shareholders: Potential for value realization through the acquisition by Kimberly-Clark, but also risks related to the consummation of the transaction and potential adverse effects on stock price.
• Employees: Changes in leadership roles and elimination of the Chief Growth Officer role may impact certain personnel. New appointments aim to strengthen capabilities and focus on execution.
• Customers: Continued focus on innovation, brand support, and digital transformation aims to improve consumer experience and product offerings. Strategic price investments may affect pricing.
• Suppliers: Efforts to improve working capital include increasing supplier payment terms closer to industry norms, which could impact supplier cash flow.
• Regulatory Bodies: Ongoing legal proceedings related to talc-based products and the need to comply with applicable laws and regulations.

Next Steps

• Execute on strategic and financial goals under the permanent CEO.
• Continue to strengthen the leadership team and bring in new talent and capabilities.
• Focus on accelerating e-commerce, innovation, and brand building for the U.S. Skin Health and Beauty business.
• Implement targeted interventions at select customers and continue the global rollout of the 'Wash Your Mouth' campaign for Oral Care.
• Step up efforts to engage with Health Care Professionals for Listerine.
• Roll out the new Listerine on-the-go sachet format across markets.
• Support the turnaround of Johnson's Baby with a global relaunch and new 'Pure Love For Precious Moments' campaign in Q4 in India and Brazil.
• Continue to provide clarity and educational tools regarding acetaminophen safety.
• Work towards consummating the proposed merger transaction with Kimberly-Clark.

Key Dates

Recommendation

The announced definitive merger agreement with Kimberly-Clark fundamentally changes the investment thesis for Kenvue. While Q3 results show mixed operational performance, the primary driver for the stock price will now be the terms and likelihood of the merger's completion. Existing shareholders should hold to realize the value from the acquisition, but new positions are speculative given the pending transaction and associated risks.

Keywords

Consumer Health, Kenvue, Q3 2025 Earnings, Financial Results, Kimberly-Clark Merger, Kirk Perry CEO, Leadership Appointments, Organic Sales, Net Sales, EPS, Gross Margin, Operating Margin, Tylenol, Zyrtec, Neutrogena, Aveeno, Johnson's Baby, BAND-AID, Listerine, Consumer Products, SEC Filing, 8-K